Does Medicare cover Ozempic & Mounjaro? And what about Wegovy or Zepbound?
Two of the most-searched Medicare questions are “does Medicare cover Ozempic?” and “does Medicare cover Mounjaro?” The answer is yes — but usually only when these medications are prescribed for type 2 diabetes.
If your goal is chronic weight management, the same medications are not covered by standard Medicare Part D. That is where the 2026 Medicare GLP-1 Bridge Program — and medications like Wegovy and Zepbound — become relevant.
Ozempic and Mounjaro are covered by Medicare Part D when prescribed for type 2 diabetes. Wegovy and Zepbound are covered for chronic weight management only through the new 2026 Medicare Bridge Program, which offers $50/month pricing for qualifying beneficiaries. The right path depends on your diagnosis, not just the medication name.
What Medicare covers, and how.
Ozempic (semaglutide)
Indication: Type 2 diabetes
Covered under standard Medicare Part D when the diagnosis is diabetes and the drug is on your plan's formulary.
Mounjaro (tirzepatide)
Indication: Type 2 diabetes
Covered under standard Medicare Part D for diabetes. May require prior authorization or step therapy.
Wegovy (semaglutide)
Indication: Chronic weight management
Excluded from standard Part D for weight loss alone. Covered through the 2026 Bridge Program at $50/month for eligible patients.
Zepbound (tirzepatide)
Indication: Chronic weight management
Excluded from standard Part D for weight loss alone. Available through the 2026 Bridge Program at $50/month for eligible patients.
Wegovy or Zepbound
Indication: Sleep apnea or MASH with fibrosis
Covered under standard Part D when prescribed for these specific FDA-approved conditions, not weight loss.
Coverage depends on your specific Medicare plan, formulary, and clinical diagnosis. Prior authorization, step therapy, and quantity limits are common. The Bridge Program is a federal access program, not a Part D insurance benefit.
Weight loss needs a different pathway.
Federal law prohibits standard Medicare Part D from covering drugs prescribed primarily for weight loss. That is why Ozempic and Mounjaro are covered for diabetes, but the same active ingredients — when FDA-approved and prescribed for weight loss — fall into a different category.
The Medicare GLP-1 Bridge Program was created to fill that gap. Starting July 1, 2026, eligible Medicare beneficiaries can access Wegovy or Zepbound for chronic weight management at a flat $50 per month, regardless of whether they have diabetes.
So the question is not “which medication is better?” It is “which pathway matches your diagnosis and your goals?”
Four things that determine your path.
Medicare Part D enrollment
You must be enrolled in Medicare Part D or a Medicare Advantage plan that includes prescription drug coverage.
A weight-management diagnosis
The Bridge Program is for chronic weight management, not diabetes. If you have diabetes, Ozempic or Mounjaro may already be the covered path through Part D.
Clinical eligibility
BMI, weight-related health conditions, and a review of your medical history and medications determine whether a GLP-1 is appropriate and safe.
Enrollment support
At Storm Wellness Northwest, we help Clark County patients review their coverage options, determine the right medication, and navigate the Bridge Program enrollment process.
Related guides.
What is metabolic health?
How metabolic health is measured and why it matters for weight management and Medicare patients.
Does Medicare cover Wegovy & Zepbound in 2026?
The full guide to Part D exclusions, the July 1 launch, and the $50/month Bridge Program.
Wegovy vs Zepbound for Medicare
How the two weight-management medications compare side by side.
Who qualifies for the Bridge Program
A plain-English walkthrough of the clinical criteria and what to expect at consultation.
Find the right coverage path for you.
A consultation with Renee Storm, APRN reviews your diagnosis, current medications, and Medicare plan — and maps out whether Part D or the 2026 Bridge Program is the better fit.